Glucagon Formulation Stability Signals

This single-study briefing examines a comparative experimental investigation of glucagon, a therapeutic peptide used to treat hypoglycemia. The authors compared structural and stability properties across an aqueous condition described as prone to aggregation and two formulation conditions representing a lactose-containing acidic preparation and a ready-to-use DMSO/trehalose preparation. Its contribution is mechanistic: it addresses molecular conformation, chemical stability, and aggregation-relevant structural regions rather than treatment effectiveness in people. [pmid:42557738]

Evidence

The reported design was a comparative experimental study of glucagon under three solution or formulation conditions. The experimental material was glucagon samples, not a patient population or animal model. Solution A was 1 mg/mL glucagon in aqueous solution at pH 3.5; Formulation B was 1 mg/mL glucagon in aqueous solution with 107 mg/mL lactose at pH 2.5; and Formulation C was 5 mg/mL glucagon in DMSO with 56 mg/mL trehalose dihydrate and 6 mg/mL sulfuric acid. The sample size was not located in the available extraction. [pmid:42557738]

Methods included circular dichroism spectroscopy, fluorescence spectroscopy, two-dimensional proton NMR experiments using TOCSY and NOESY, and RMSD analysis of structural regions. Circular dichroism spectra were collected for the aqueous systems, while the stated NMR experiments were performed on Solution A and Formulation C. These methods were used to compare conformation and stability over time rather than to evaluate clinical outcomes. [pmid:42557738]

The strongest structural result was the reported change in RMSD within Solution A. Initial RMSD values were 0.0628 Å for residues 7 Thr-Leu 14 and 0.0169 Å for residues 18 Arg-Asp 21. After 1 day, RMSD for residues 7 Thr-Leu 14 was 2.33 Å, whereas the value for residues 18 Arg-Asp 21 was 0.00680 Å. The authors interpreted this pattern as significant destabilization of the first helix segment while the latter region remained more stable, identifying these regions as relevant in early aggregation. No confidence interval or p-value was located for this result. [pmid:42557738]

Formulation C was reported to remain essentially unchanged during the experiment, with measured purities of 98.34%, 98.36%, and 98.37%. The authors described these results as indicating high chemical stability over the monitored period. The reported purity data were identified as data not shown, and the duration of that monitored period was not specified in the available extraction. [pmid:42557738]

Across the investigated environments, the authors reported that structural destabilization consistently began at the C-terminal region and that the 11 Ser-Leu 14 segment remained structured. They therefore presented preservation of the C-terminal region and stabilization of the 11 Ser-Leu 14 motif as considerations for glucagon formulation design. [pmid:42557738]

Analysis — Formulation stability interpretation

The central signal is a structure–stability relationship rather than evidence of superior therapeutic performance. The regional RMSD pattern in Solution A provides a time-linked observation that one helical segment became less structurally consistent after 1 day while the 18 Arg-Asp 21 region remained comparatively stable. Together with the observation that destabilization began at the C-terminal region, this supports the authors’ mechanistic focus on regional conformational preservation as an aggregation-relevant formulation objective. It does not show that modifying either region will improve patient outcomes, biological activity, emergency-use performance, or shelf life in a particular product. [pmid:42557738]

The stability signal for Formulation C is chemically encouraging within the reported experiment, but it should be read in the context of a formulation comparison rather than as a clinical comparison. The study examined materially different solvent and excipient environments, including differing glucagon concentrations, so the observations identify candidate determinants associated with the tested conditions. They do not isolate the independent effect of DMSO, trehalose, acidity, concentration, or their combinations. The authors’ formulation-design framing is consequently hypothesis-generating for peptide development, with confirmation requiring studies designed to separate those contributions and to test product-relevant performance. [pmid:42557738]

No clinical significance can be assigned from the reported spectroscopy, NMR, RMSD, or purity observations. The work is valuable for locating possible molecular vulnerabilities and for motivating preservation of particular glucagon regions, but it does not compare patient-facing endpoints or establish that an observed structural difference translates into a clinically meaningful difference. [pmid:42557738]

Limitations

Reliable structural assignment and calculation could not be performed for Formulation B because its high lactose concentration masked glucagon resonances in the alpha-proton region. The investigators reprepared glucagon at pH 2.5 without lactose for structural analysis, which allowed examination of an acidic solvent system but means the full lactose-containing formulation was not directly assigned through that NMR approach. [pmid:42557738]

The available extraction does not locate sample size, and it does not specify the monitored period associated with the Formulation C purity values. In addition, those purity results were reported as data not shown. These reporting gaps limit assessment of experimental precision, replication, duration, and the evidentiary detail behind the chemical-stability description. [pmid:42557738]

The study used prepared glucagon samples under defined solution and formulation conditions. Its results should therefore be interpreted as experimental formulation evidence, not as evidence about comparative clinical safety, efficacy, dosing, or outcomes for people using glucagon. [pmid:42557738]